# Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

> **NCT02736721** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 41 (actual)

## Conditions studied

- Myelogenous Leukemia, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a

## Key facts

- **NCT ID:** NCT02736721
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02736721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02736721, "Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02736721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*